Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Govorestat (AT-007) in Adult Classic Galactosemia Extension
NCT05418829Phase 3Unknown
- Sponsor
- Applied Therapeutics, Inc.
- Start
- Oct 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of govorestat in Classic Galactosemia (GALT), sponsored by Applied Therapeutics, Inc. Primary endpoints: Incidence of Adverse Events at 12 months, Clinical Laboratory Test Results at 12 months and 1 more. Status: unknown.
02
Drugs
govorestat
03
Conditions
Classic Galactosemia (GALT)
Beyond the preview
Go deeper on NCT05418829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418829.